QLINE
Q-Line Biotech (QLINE)
Latest view
Neutral
as of 7 Jun 2026 · not a recommendation
Evidence timeline
What management said
from NSE earnings-call filings · extracted, not interpreted
Call 30-Jun-2026 · transcript PDF
Outlook, as stated
For FY27, our priorities will include increasing utilization of our manufacturing facilities, commercialization of additional products from unit number 4, launching new diagnostic instruments, expanding exports and maintaining disciplined cost management.
Based on our current business momentum and growth initiative, we are targeting revenue growth of approximately 30% to 35% of FY27, while maintaining a strong focus on profitability and also capital efficiency.
Based on the current visibility, we are targeting revenue growth of approximately 30% to 35% while continuing to focus on profitability and return ratios.
3.44
concrete references per 100 words spoken — counts, currency, units and
named periods, not adjectives
Chart exhibits
as drawn · not updated since
No forward scenario
the call carried no figure that bridges to earnings growth.
Price chart
45 sessions to 31 Jul 2026 ·
daily close ·
our own broker data